Mold-Tek Technologies Limited (MOLDTECH)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2FY27 standalone turnover up 25% to INR 46.64 Cr; H1 standalone PAT 4.4x to INR 20.19 Cr
- Consolidated H1 PAT up 375% to INR 18.62 Cr vs last year
- BIW segment downsized; focus on poles & towers, structural steel detailing, and new civil/land development domain
- Beryl acquisition expected to breakeven in Q3FY27; new orders and design focus improving outlook
- Standalone revenue growth guidance 20-25% and consolidated 18-20% for next 12-18 months
- Employee productivity improved 15-16%; automation and training ongoing to boost efficiency
- Data center and utility services ramping up; fixed teams growing with new contracts
- Acquisition focus on structural design companies to expand high-value services
- Risks include US demand shifts; residential and civil segments to offset volatility
- Multiple analyst queries on margin sustainability and growth drivers; management confident on positive trajectory
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MOLDTECH — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MOLDTECH to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Mold-Tek Technologies Limited
Important.
The summary above is generated automatically from Mold-Tek Technologies Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.